

HELPING PATIENTS SURVIVE THE RAVAGES OF DEADLY INFLAMMATION WORLDWIDE



CytoSorbents™

Working to Save Lives Through Blood Purification

NASDAQ: CTSO
Biotech Showcase Presentation
January 10, 2016

Safe Harbor Statement

Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical Inc. and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies' products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company's Form 10-K filed with the Securities and Exchange Commission on March 9, 2016 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.



CytoSorbents is A Leader in Critical Care Immunotherapy



Leading the Prevention or Treatment of
Life-Threatening Inflammation
in the ICU and Cardiac Surgery using
CytoSorb® Blood Purification



CytoSorbents At a Glance


- NASDAQ-traded (CTSO): \$6.20 per share
- International footprint across two wholly-owned operating subsidiaries
 - CytoSorbents Medical, Inc - Monmouth Junction, NJ
 - Headquarters, ISO 13485 manufacturing, QA/QC, R&D
 - CytoSorbents Europe GmbH: International sales office - Berlin, Germany
 - CytoSorbents Switzerland GmbH
- Flagship product, CytoSorb[®], is E.U. approved, with 20,000+ treatments and distributed in 42 countries
- Strategic Partnerships with Fresenius Medical Care, Biocon, and Terumo
- Strong government support with \$18M+ in grants, contracts, other funding
- ~70 employees and consultants worldwide
- Pursuing U.S. approval of CytoSorb[®] in cardiac surgery via REFRESH I & II
- Doubled 2016 CytoSorb sales to \$8.2M vs \$4.0M in 2015 with blended gross margins > 65%
- Accelerated growth expected in 2017 with numerous potential catalysts




Severe Inflammation is Common in the ICU

Millions worldwide admitted to the intensive care unit annually with deadly inflammatory conditions

Sepsis



ARDS



Burn Injury



Trauma




Pancreatitis



Influenza



Cancer Immunotherapy




- Severe inflammation is driven by the excessive production of cytokines and other inflammatory mediators that can create a “cytokine storm” that anti-inflammatory drugs cannot control
- Patients are kept alive with “life support” machines that do not help them get better, but merely keep them alive until hopefully the body starts to heal itself
- Staggering costs: Lack of “active” therapies leads to patients lingering days to weeks in the ICU at \$4,300 per day in the U.S.¹ where 1 in 3 patients will die
- Hospitals spend 10-15% of their operating budget and the U.S. spends \$110B on critical care



Cardiac Surgery Drives Dangerous Inflammation

- Heart disease is the leading cause of death worldwide driven by smoking, unhealthy lifestyles, and an aging population
- ~1.5M Open Heart Surgeries performed globally
 - Coronary artery bypass graft surgery
 - Valve repair or replacement
 - Heart or lung transplantation
 - Congenital defect repair
 - Aortic reconstruction
- Complex cardiac surgeries require long heart-lung machine pump times, resulting in:





- ↑ Hemolysis and free hemoglobin
- ↑ Inflammatory mediators, cytokines, and complement
- ↓ Levels of nitric oxide, causing decreased blood flow to vital organs

Severe inflammation and reduced blood flow can lead to kidney, lung, and/or heart failure in many patients following surgery

Massive Inflammation Causes Organ Failure

Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU.



Little can be done to prevent or treat it today



CytoSorbents

Working to Save Lives Through Blood Purification


CytoSorb[®] Removes the Fuel to the Fire

- CytoSorb[®] targets the \$20+ billion opportunity in critical care and cardiac surgery
- Approved in the European Union as the only specifically approved extracorporeal cytokine filter
- Approved for use in any situation where cytokines are elevated
- Removes cytokines and many other inflammatory mediators such as free hemoglobin, bacterial toxins, myoglobin, and activated complement
- Works with standard dialysis and heart-lung machines
- Safe and well-tolerated: In ~20,000 human treatments, up from 9,000 a year ago



Powerful Blood Purification Technology

The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood




- Protected by 31 issued US patents and multiple applications pending
- Manufactured at our ISO 13485 certified facility in New Jersey
- One of the highest grade medical sorbents on medical market today




CytoSorb[®] is Plug and Play with Existing Machines

Easy to Use, No Special Equipment or Training Required




- Place a temporary dialysis catheter in a major vein
- Connect the device to a standard dialysis machines found in hospitals worldwide
- Pump blood out of the body and through the cartridge
- The polymer beads directly contact blood and remove unwanted or toxic substances
- “Purified” blood is pumped back into the patient
- Can treat 70+ total blood volumes per 24 hr treatment
- Each treatment uses a new cartridge

Goal: To Prevent or Treat Organ Failure




Improve
Patient
Outcome
and
Survival




Decrease
Costs Of
ICU and
Patient
Care

Sepsis



ARDS



Burn Injury



Trauma



Pancreatitis



Influenza



Surgical



The Potential to Revolutionize Critical Care Medicine






CytoSorbents

Working to Save Lives Through Blood Purification

The World Needs **CytoSorb**®



H1N1



CytoSorbents
Working to Save Lives Through Blood Purification

\$18 Million in U.S. Government Support

- DARPA awarded \$3.8M five year (2012-present) contract as part of “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins
- U.S. Army awarded ~\$1.7M SBIR contracts for trauma and burn injury research and hyperkalemia (2011-present)
- JPEO-CBD awarded \$150K Phase I SBIR contract for fungal mycotoxin removal (2016-present)
- U.S. Dept of Health and Human Services awarded \$0.5M grant (2010) for therapies that can save lives and reduce costs under the QTDP Program
- NIH grant awarded \$7M five year (2006-2010) to University of Pittsburgh and Dr. John Kellum to research CytoSorb beads for treatment of sepsis
- NIH/NHLBI and SOCOM awarded \$1.7M Phase I & II SBIR contracts for HemoDefend blood purification technology to improve the quality/safety of blood transfusions (2013- present)
- Defense Health Agency awarded a \$150K Phase I SBIR contract to treat hyperkalemia
- More than \$2M in New Jersey funding for research-related net operating losses



Driving to Operating Profitability



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorb® Is a High Margin Razorblade

- CytoSorb is a high margin “razorblade” disposable that is fully compatible with the existing installed base of dialysis and ECMO “razor” machines in the ICU, and heart-lung machines in the operating room
- Average Selling Price is approximately \$1,000 per cartridge
- Approximately 1 - 10 cartridges are typically used per patient. Open heart surgery uses 1-2 cartridges, treatment of sepsis uses 3-5 cartridges. An entire course of treatment for sepsis is roughly the cost of 1 day in the ICU
- Blended gross margins are >65%, but with economies of scale and manufacturing efficiencies, this is expected to be closer to 80%
- In Germany, 400 hospitals have >400 beds. Each of these hospitals will see 300-600 sepsis patients per year. At 3-5 cartridges per patient, each hospital has a total potential CytoSorb revenue of \$1-3M for sepsis alone

Direct Sales: Expanded to 5 Countries

CytoSorbents' direct sales force focused on most major university and public hospitals in Germany, Austria, Switzerland, Belgium and Luxembourg. German market alone is \$1.0-1.5 billion



Dr. Christian Steiner, MD
Vice President – Sales and Marketing and General Manager
CytoSorbents Europe GmbH



Stefan M. Baudis
International Sales Director



Dr. Joerg Scheier, MD
European Medical Director



Dr. Volker Humbert, MD
Director – Clinical Affairs



Dominik Gutzler
Head of Product Management



Dr. Rainer Kosanke, PhD
Head of Scientific Marketing



Alexandru Bojan
Business Manager Export



Hans-Juergen Kraus
Regional Sales Manager
Southern Germany



Matthias Hoeldtke
Regional Sales Manager
Southeast Germany



Uwe Gerks
Regional Sales Manager
Northern Germany



Andreas Gassmann
Sales Representative
Southern Germany



Christian Koptik
Regional Sales Manager
Austria



Martin Scherer
Regional Sales Manager
Southwest Germany



Andreas Pendleler
Regional Sales Manager
Western Germany



Steffen Martens
Regional Sales Manager
Northeast Germany



Oliver Lupoli
Country Sales Manager
Switzerland



Harriet Adamson
Clinical Study Manager



Eva Wechsler
Application Specialist



Ilona Otto
Sales Assistant/Customer Support
Direct



Petra Hoffman
Sales Assistant/Customer Support
International



Anke Applehoff
Application Specialist
Direct



Franziska Preissing
Reimbursement Manager



CytoSorb® Distributed in 42 Countries



IntensivMed




CytoSorbents

Working to Save Lives Through Blood Purification

Quarterly Product Sales


Seventh consecutive quarter of product sales growth
Sixth consecutive quarter of record sales



Range:
\$2.5-2.7M




Annual Product Sales



Operating Profitability Expected in 2 Years

Operating profitability is expected within 2 years at ~\$20M in sales, at which point an estimated 40-50 cents on every dollar drops to the bottom line



Product sales continue to grow rapidly while increases in fixed non-clinical, non-cash expenses taper off

Key Catalysts for Growth In 2017 and Beyond

Dedicated Reimbursement In Germany

- Announced last month that CytoSorb has achieved a permanent, dedicated reimbursement code in Germany – our most important market and the largest medical device market in the European Union
- Validates the importance of our therapy to physicians in the country
- Was achieved very rapidly by the initiative and strong support of several major medical societies across different medical specialties
- Effective January 1, 2017, the new code is expected to result in much higher reimbursement compared to the more generic code we have used, which in many cases led to inadequate reimbursement, impeding usage and sales
- Expected to catalyze major increases in usage and CytoSorb sales in Germany, and positively impact reimbursement in other countries

Geographic Expansion – A Growth Engine

January 2016

January 2017


Contributing to Revenue			Not Yet Contributing to Revenue		
#	Country	Population (M)	#	Country	Population (M)
1	Germany	81	16	France	66
2	Austria	9	17	Poland	39
3	Switzerland	8	18	Sweden	10
4	United Kingdom	64	19	Denmark	6
5	Italy	60	20	Norway	5
6	Turkey	75	21	Finland	5
7	India	1,200	22	Russia	144
8	Sri Lanka	21	23	UAE	9
9	Netherlands	17	24	Qatar	2
10	Romania	20	25	Kuwait	3
11	Ireland	5	26	Oman	4
12	Moldova	4	27	Bahrain	1
13	Australia	23	28	Iraq	33
14	New Zealand	5	29	Jordan	7
15	Saudi Arabia	29	30	Yemen	24
			31	Vietnam	90
			32	Israel	8
Total		1,621	Total		456

Contributing to Revenue			Not Yet Contributing to Revenue		
#	Country	Population (M)	#	Country	Population (M)
1	Germany	81	32	UAE	9
2	Austria	9	33	Qatar	2
3	Switzerland	8	34	Kuwait	3
4	United Kingdom	64	35	Oman	4
5	Italy	60	36	Bahrain	1
6	Turkey	75	37	Iraq	33
7	India	1,200	38	Jordan	7
8	Sri Lanka	21	39	Yemen	24
9	Netherlands	17	40	Israel	8
10	Romania	20	41	Iceland	0.3
11	Ireland	5	42	Iran	78
12	Moldova	4			
13	Australia	23			
14	New Zealand	5			
15	Saudi Arabia	29			
16	France	66			
17	Poland	39			
18	Sweden	10			
19	Denmark	6			
20	Norway	5			
21	Finland	5			
22	Russia	144			
23	Spain	46			
24	Portugal	10			
25	Vietnam	90			
26	Hungary	10			
27	Czech Republic	11			
28	Slovakia	5			
29	Chile	18			
30	Belgium	11			
31	Luxembourg	1			
Total		2,098	Total		169.3

We continue to add new and existing distributors into the “contributing to revenue” category and many other countries

Focus on Clinical Data


- Broad clinical program in Europe with 58 investigator-initiated studies in various stages, including several that have completed and nearly half have started and/or are enrolling
- These studies run the gamut from sepsis, cardiac surgery, post-operative inflammation, liver failure, trauma, and many other applications
- In addition, we have a number of company sponsored trials in cardiac surgery and sepsis that will start next year, in both Europe and the U.S.
- There are more than two dozen publications ranging from case reports, case series, and small randomized controlled studies that have been submitted or are being prepared for submission
- These data will be extremely helpful in driving continued usage and adoption, as well as reimbursement of CytoSorb in many different markets



U.S. REFRESH I Trial – Safety Confirmed

REduction in FREe Hemoglobin

- 40-patient, eight-center study evaluating the safety and efficacy of intra-operative use of CytoSorb® in a heart-lung machine during complex cardiac surgery in elective, non-emergent cardiac surgery > 3 hours
 - Aortic reconstruction, CABG redos, multiple valve replacements, etc
- Working with major cardiac surgery centers
 - Baylor College of Medicine and Texas Heart Institute
 - Baystate Medical Center
 - Columbia University
 - Cooper University Hospital
 - University of Kentucky
 - University of Maryland
 - University of Pennsylvania
 - University of Pittsburgh Medical Center
- Primary endpoints were safety and reduction in free hemoglobin



CytoSorbents

Working to Save Lives Through Blood Purification

REFRESH I Trial – Safety

REduction in FREe Hemoglobin Trial



- A total of 46 patients were enrolled with ~40 patients with evaluable biomarker data
- The Data Safety Monitoring Board (DSMB) evaluated all reported adverse and serious adverse events in the control and treatment arms, and concluded there was no safety issue with CytoSorb therapy, achieving the primary safety endpoint of trial.
- First RCT using CytoSorb in high risk cardiac surgery, demonstrating safety
- We plan to present safety, free hemoglobin, and other clinical data at the AATS cardiac surgery conference in April
- Following a meeting with the FDA to discuss the data and clinical path, the company expects to begin the REFRESH 2 trial in the first half of 2017 with approval possible in 2018-19 depending on the clinical path (de novo 510(k) vs PMA)



Establish Strategic Partnerships To Maximize Value



Critical Care,
High Risk
Surgery

HemoDefend




Blood
Collection &
Transfusion

CytoSorb-XL




Sepsis,
Critical Care,
High Risk
Surgery

**Potassium
Sorber**




Severe
Hyperkalemia

ContrastSorb




CT Imaging,
Interventional
Radiology

DrugSorb



Drug
Overdose,
Chemo
Removal

BetaSorb



Improving
Dialysis

CE Mark Approved

Under Development

Three Major Partnerships, Potential for More

LivaNova

TERUMO

THORATEC CORPORATION

Medtronic

Cardiac Surgery

HeartWare

MAQUET
GETINGE GROUP

HAEMONETICS®
THE Blood Management Company™

BARD

Teleflex®

Critical Care or Catheters

angiodynamics

NxSTAGE®
Invent. Improve. Inspire.

NIPRO
MEDICAL CORPORATION

FRESENIUS
MEDICAL CARE

Renal Dialysis

Davita.

Baxter

BRAUN
SHARING EXPERTISE

NIKKISO

GAMBRO®

CytoSorbents
Working to Save Lives Through Blood Purification

macopharma
DESIGNED FOR LIFE

GRIFOLS

HAEMONETICS®
THE Blood Management Company™

Blood Transfusion

FRESENIUS
KABI

TERUMOBCT
Unlocking the Potential of Blood

CERUS

Johnson & Johnson **Biocon**

AMGEN® Biotech and Immunotherapy

Roche

Celgene

abbvie

sanofi aventis

CytoSorbents
Working to Save Lives Through Blood Purification

*Companies listed here are used simply as examples of companies in these respective verticals. We make no other representations to our relationship with any of these companies.

Expanded Fresenius Partnership


- CytoSorbents entered into a strategic partnership with Fresenius Medical Care (FMC) – the world's largest provider of products and services for individuals with renal diseases – at the end of 2014
- As part of its growth strategy in acute care, FMC launched CytoSorb sales and marketing for critical care applications in May 2016 in ICUs across France, Poland, Denmark, Norway, Sweden and Finland
- Yesterday, FMC and CytoSorbents announced an expansion of the original partnership and a new co-marketing agreement for worldwide CytoSorb markets
- Agreement brings increased commitment with 3-year renewal, guaranteed minimum orders of CytoSorb, and establishes joint CytoSorb marketing collateral and efforts in active sales territories



TERUMO Launched in December

TERUMO CARDIOVASCULAR GROUP

- Entered into a multi-year partnership with Terumo Cardiovascular Group, a global leader in medical devices for cardiac and vascular surgery
- Initial exclusive distribution of CytoSorb® in France, Denmark, Norway, Sweden, Finland, and Iceland
- Launched December 2016
- Strong validation of our technology and opens door to potential expansion to other countries, such as Japan – the second largest medical device market in the world



Biocon Has Renewed Focus on CytoSorb



Treat Primary Infection with
Antibiotics



Treat Massive Inflammatory
Response with CytoSorb

- Biocon is the largest biopharmaceutical company in India
- Significant growth in India with expansion into Sri Lanka
- They have renewed their commitment to CytoSorb with its own division, sales force, and funding for small clinical studies



Increase Investor Awareness



NASDAQ Capital Market Listed

- Clean capital structure with average daily trading value of ~\$425,000



Included in Russell Microcap Index

CytoSorbents Corporation Set to Join Russell Microcap Index

6/19/15

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, is set to join the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 26, 2015, according to a [preliminary list of additions](#) posted on June 12, 2015.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "We are pleased to be included in the Russell Microcap Index, a significant corporate achievement that is expected to increase visibility and exposure of our company and life-saving technology to the broader investment community. This complements our continued institutional investor outreach, where the response has been extremely positive to date."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately \$5.7 trillion in assets are benchmarked to the Russell's U.S. indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 1000 and the Russell indexes reconstitution, go to "Recon Central"

Strong Technology Validation of CytoSorb

**\$20M in Grant,
Contract, and
Other Research
Funding**

**17,000
Human Treatments
and Growing**



CytoSorbents

Working to Save Lives Through Blood Purification

Increasing Media Coverage

Forbes

Jennifer Hicks Contributor
I write about science, robotics & innovative technologies in Europe.
Opinions expressed by Forbes Contributors are their own.

TECH 8/24/2016 @ 4:09PM | 2,950 views

This Blood Filtering System Could Help Lower The Risk of Death From Inflammatory Infections




A new blood filter. (Image credit: Kurt Paulus, Munich)

Trauma to the body comes in many forms – severe burns, gun shot wounds, liver failure, drug overdose, sepsis – which can be deadly. Treating these types of trauma to the body means people end up in the intensive care unit (ICU).



Exclusive: Cytosorbents CEO On How Its Blood Purification Technology Can Change Healthcare

Jayson Derrick (/users/jayson-derrick), Benzinga Staff Writer | FOLLOW
August 15, 2016 8:54am | [Comments](#)



imagecache/1024x768xUP/images/story/2012/blood/7302_1280_0.jpg

cytosorbents Corp ▼ CTSO 5.23% (http://benzinga.com/stock/ctsco#NASDAQ) is a critical care company that focuses on the commercializing its main product, CytoSorb – a blood purifier used on preventing or treating multiple organ failures.



GEN Genetic Engineering & biotechnology News

SiriusXM SATELLITE RADIO

DOCTOR RADIO

Medtech Insight

Pharma intelligence

CytoSorbents Expanding Marketing Reach Of CytoSorb Blood Purifier

by Reed Miller
@MedtechReed | reed.miller@informa.com

Executive Summary

CytoSorbents is sponsoring the REFRESH I trial of its CytoSorb extracorporeal cytokine adsorber in the US, which the company hopes will support approval of a pivotal trial of the device for reducing reduce plasma free hemoglobin and cytokines in patients undergoing complex cardiac surgery.

CytoSorbents
Working to Save Lives Through Blood Purification

Increasing Analyst Coverage

AEGIS CAPITAL CORP

October 26, 2016

Biotechnology
Jason Wittes
(646) 502-2452
jwittes@aegiscap.com

Initiating Coverage

Cytosorbents
Rating: Buy
Initiating With A Buy and \$20 Price Target

Investment Highlights:

Key Metrics	\$5.90
CTSO - NASDAQ	\$20.00
Price Target	\$8.10 - \$3.11
52-Week Range	25.7
Shares Outstanding (mm)	\$151.6
Market Capitalization (mm)	5%
Institutional Ownership	66.33

H.C. WAINWRIGHT & CO.

Earnings Update
Medical Device
May 10, 2016

Swayampakula Ramakanth, Ph.D.
212-356-0544
sramakanth@hcresearch.com

Sean Lee
212-356-0521
slee@hcresearch.com

CytoSorbents Corp (CTSO)
Rating: Buy

Fresenius to Rollout in May; REFRESH to Report in 3Q16; Reiterate Buy

Financial update and changes to our model. CytoSorbents reported 1Q16 financial results and held a conference call on May 9. The company reported revenues of \$1.8M, higher than our estimate of \$1.6M.

Stock Data	05/09/2016
Price	\$4.47
Exchange	NASDAQ

B RILEY

Discovery Group

Utilizing Blood Purification to Remove Fuel From the ICU's Biggest Killers; Initiating Coverage with a Buy & \$11.25 Price Target

Andrew D'Silva | (818) 746-9523
adsilva@brileyco.com

Summary and Recommendation
CytoSorbents (CTSO) has developed a potentially breakthrough therapy to extract inflammatory mediators such as cytokines and toxic proteins from blood in critically ill patients as well as those undergoing cardiac surgery. The company's lead product

CytoSorbents Corporation (CTSO)
Healthcare: Medical Technology
Buy: \$11.25 PT
Friday, October 7, 2016

WBB Securities, LLC

Stephen G. Brozak • sbrozak@wbbsec.com • (908) 518-7610

February 25, 2015

INITIATING COVERAGE - FEBRUARY 25, 2015
CytoSorbents Corporation (NasdaqCM: CTSO)
Initiating Coverage with a Speculative Buy Rating and One-Year Price Target of \$13.00

12 Month Target Price	\$13.00
12 Month Trading Range	\$4.40-\$12.87
Market Capitalization (Mil)	\$267.87

MAXIM GROUP

EQUITY RESEARCH
INITIATION

Biotechnology
CTSO - NYSE
May 23, 2016

Closing Price 05/23/2016 \$4.20 Buy

Rating: Buy \$8.00
12-Month Target Price: \$3.11 - \$8.10
52-Week Range: 107
Market Cap (M): 25.4
Shares O/S (M): 75.4%

Summary
A New Paradigm in Sepsis and More; Initiating Coverage with a Buy Rating and a \$8.00 Price Target

CytoSorbents is now commercializing its CE-approved product CytoSorb in the EU (direct in Germany, Austria and Switzerland) and in a total of 32 countries worldwide (ex.US) for complications related to life-threatening inflammatory diseases such as sepsis, trauma, burn injury, liver failure, and lung injury as well as cardiac surgery.

CytoSorb has the potential to become part of the standard of care for sepsis, a top-10 cause of death worldwide. It is an extracorporeal blood purifier (a filter) that targets the immunological "cytokine storm" that accelerates organ dysfunction and failure and ultimately death. By extending the treatment window for these patients, the product could be the difference between life and death for some patients.

CytoSorb has yet to build sales traction. Revenues last year from both direct sales and distributorship amounted to a total of only \$4M. Introducing a new treatment paradigm to these very sick patients will take time for adoption.

Total Revenues ('000)	2015A	2016E	2017E
1Q	981	1,810A	4,723
2Q	1,233	3,091	4,917

Zacks Small-Cap Research

June 2, 2016
Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474
10 S. Riverside Plaza, Chicago, IL 60606

CytoSorbents Corporation (CTSO-NASDAQ)

CTSO: Fresenius Commences Sales, DSMB Recommends Continuation of REFRESH I

OUTLOOK
We view 2015 as somewhat of a re-grouping year on the income statement - although "re-grouping" should be put into context given that product sales grew 29% - and which would have been almost 50% growth if not for an FX headwind. And if not for the sales force disruption earlier in the year, product sales growth would likely have been even significantly stronger.

We expect to see accelerating product sales growth as well as more strides on the operational front in 2016. In addition to Fresenius coming online, expansion into other geographic territories (in addition to those detailed by Fresenius), an expected continued regular flow of clinical data (including that from the patient registry as well as REFRESH I), potential additional production gains from the direct sales force, sales through Biocon could also accelerate further. And the cardiac-surgery channel also holds significant potential. Consummation of a partnering agreement could further this opportunity.

Based on our 10-year DCF model, which uses a 13% discount rate to account for certain risks and uncertainties that CytoSorbents faces, and a 2% terminal growth rate, the shares are valued at approximately \$12.50.

Current Price (06/01/16) \$4.48
Valuation \$12.50



Newly Launched Corporate Website

The screenshot shows the CytoSorbents corporate website. At the top left is the logo "CytoSorbents™". To its right are social media icons for Twitter, Facebook, LinkedIn, and YouTube. Further right is a search bar with the text "Search" and a magnifying glass icon. Below the logo and social media icons is a navigation menu with links: "Home", "About", "Products", "Technology", "Investor Relations", "News", and "Contact".

The main banner features a blue background with a globe and digital data lines. On the right side of the banner is a product image of a "CytoSorb 300 ml Device". The text in the banner reads: "A GLOBAL LEADER IN CRITICAL CARE IMMUNOTHERAPY" and "Treating deadly inflammation in the ICU and cardiac surgery".

Below the banner are three columns of content:

- TREATING DEADLY INFLAMMATION**: Accompanied by an image of a lighthouse and a product. Text: "CytoSorb® is a unique blood purification therapy to control deadly inflammation in life threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 39 countries around the world."
- THE POWER OF THE BEAD**: Accompanied by an image of a metallic bead. Text: "Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption."
- INFORMATION FOR INVESTORS**: Accompanied by an image of three business professionals. Text: "CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders."



CytoSorbents

Working to Save Lives Through Blood Purification

CytoSorbents Has Tremendous Potential

CytoSorbents is a hybrid: Combines the greater visibility and lower risk of a medical device company with product sales with the upside potential of biotech

CytoSorbents plans to achieve key milestones for investors within the next 2 years

- We expect to exceed \$10 million in sales this year, a key revenue threshold for many fundamental institutional investors
- Following discussions with the FDA, we plan to initiate a pivotal, registration trial for CytoSorb in the U.S., putting a time-line, for the first time, on a potential U.S. approval
- We expect to achieve operating profitability, with expanding sales and gross margins, within the next 2 years, completely changing our investment profile

CytoSorb is helping to save lives throughout the world



***Providing Hope
in a helpless situation***



HELPING PATIENTS SURVIVE CRITICAL ILLNESSES WORLDWIDE



CytoSorbents™

Working to Save Lives Through Blood Purification

NASDAQ: CTSO

Dr. Phillip Chan, MD, PhD – CEO

pchan@cytosorbents.com